Somite
Boston
About Somite
Somite.ai is a venture-backed company aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle: It enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications. The company's pipeline includes the promising SMT-M01 program for Duchenne muscular dystrophy (DMD) and the SMT-B01 program for metabolic disorders. Incorporated in Oct. 2023, Somite.ai has raised over $10m to date.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $104.8M
- Last round: Series Unknown (Aug 2025)
- Website: somite.ai
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/somite-41890 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.